IDC Projects Global Security Spending to Reach $308 Billion in 2026 Driven by AI Threats
AI 摘要Channel Impact47天前United States
•IDC forecasts global security spending will hit $308 billion in 2026, up from prior years, with the U.S. leading at $150 billion fueled by financial services, healthcare, and government sectors.
•Software will account for over 50% of spending, including identity and access management, endpoint security, and analytics, growing 14% year-over-year amid AI-powered threats.
•Fastest-growing categories like CNAPP and data security software address AI workloads and non-human identities, as companies prioritize integrated architectures for resilience.
•Analyst Monika Soltysik notes organizations focus on visibility, automation, and data protection amid rising regulatory pressure and geopolitical cyber risks.
• Amazon Web Services achieved its fastest growth in nearly four years, fueled by AI solutions and enterprise adoption.
• Key drivers include innovations like Bedrock and Kiro amid surging cloud spending.
• AI is sparking a new wave of infrastructure investments in the US market.
• SoftBank is preparing Roze AI, combining robotics, data centers, and AI infrastructure for a US IPO targeting $100B valuation.
• Masayoshi Son backs the venture, with potential public listing as early as late 2026 or 2027.
• Executives plan an analyst day in July, though no products or revenue plans announced yet.
• Aviatrix Inc. announced the launch of a new platform designed to contain artificial intelligence agents and enforce security controls across AI workloads without requiring changes to AI agents or code.
• The platform extends Aviatrix's Cloud Native Security Fabric with two new products: Zero Trust for AI Workloads (now generally available) and Aviatrix AgentGuard (in early access), enabling IT teams to set policies that allow or deny access to external AI services and block shadow AI with allowlists.
• The solution provides network-layer enforcement across workloads and regions, addressing the growing need to secure AI agents, large language model proxies, and agentic frameworks in enterprise environments.
• The Pentagon launched GenAI.mil in December 2025 as part of Project Maven, providing secure generative AI access to approximately 3 million Department of Defense staff members.
• The platform embeds multiple leading AI models including Anthropic's Claude, Google's Gemini, xAI's Grok, and OpenAI's ChatGPT, enabling widespread AI adoption across military operations.
• The initiative reflects the U.S. military's strategic priority to integrate advanced AI capabilities into defense operations and demonstrates significant government investment in dual-use AI technology.
• Skye AI, a home screen app for iPhone powered by artificial intelligence, raised $3.58 million in pre-seed funding while still in private testing phase.
• The funding supports development of the app, which aims to enhance iPhone user experience through AI-driven features accessible directly from the home screen.
• This investment highlights growing investor interest in mobile AI applications amid competition in the smartphone ecosystem.
• Sevii announced the launch of its Autonomous Cyber Swarm Defense (CSD) capability on April 28, 2026, to counter high-volume AI-driven cyber attacks at machine speed and scale.
• The ADR platform deploys Agentic AI Cyber Warrior agents that detect, contain, and remediate threats in under 15 minutes, reducing analyst workloads by 95% with a fixed per-asset pricing model eliminating AI token costs.
• CSD Mode features Myrmidon Defense Technology (MDT) for efficient micro-orchestration, enabling predictable budgeting without additional hires or outsourcing, as noted by Synergem Technologies CEO Frank Holt.
• Framingham, MA-based Tortugas Neuroscience raised $106 million in combined seed and Series A funding for small molecule therapies targeting neurological disorders.
• Cure Ventures led the seed round, with The Column Group and AN Venture Partners co-leading Series A on April 21.
• The investment accelerates development of treatments using validated biological targets, addressing unmet needs in US biotech.